Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nls Pharmaceutics Ltd
(NQ:
NLSP
)
0.1640
+0.0146 (+9.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nls Pharmaceutics Ltd
< Previous
1
2
3
4
Next >
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
April 19, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
March 22, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
March 20, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Company Update and Webcast Today Postponed
June 30, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
March 20, 2024
Via
ACCESSWIRE
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
March 14, 2024
Via
ACCESSWIRE
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
March 11, 2024
Via
ACCESSWIRE
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
February 23, 2024
Via
ACCESSWIRE
Notice of Deficiency with Nasdaq Continued Listing Requirements
January 12, 2024
Via
ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
December 29, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
December 01, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Election of Additional Board Members
November 28, 2023
Via
ACCESSWIRE
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
November 27, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
November 16, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
October 25, 2023
Via
ACCESSWIRE
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
October 19, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
October 12, 2023
Via
ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
August 28, 2023
Via
ACCESSWIRE
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
July 03, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Releases the Results from its Annual General Meeting
June 30, 2023
Via
ACCESSWIRE
CORRECTION FROM SOURCE: NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 19, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Company Update Webcast
June 19, 2023
Via
ACCESSWIRE
NLS Pharmaceutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
June 15, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Announces Positive Safety Data From In Vitro CYP450 and Transporter Mediated Drug-Drug Interaction Studies of Mazindol
June 14, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
May 08, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Presents Latest Clinical and Preclinical Data at SLEEP 2023
May 04, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
May 02, 2023
Via
ACCESSWIRE
NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology
April 25, 2023
Via
ACCESSWIRE
Why Did Bullfrog AI Stock Jump More Than 50%?
April 05, 2023
Trading volume and share price for BFRG took significant leaps forward on news the digital biopharmaceutical company will partner with Johns Hopkins University.
Via
MarketBeat
Topics
Artificial Intelligence
Initial Public Offering
Exposures
Artificial Intelligence
Securities Market
NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
March 27, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.